Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients.
10.4093/dmj.2011.35.5.529
- Author:
Hyun Jeong JEON
1
;
Tae Keun OH
Author Information
1. Department of Internal Medicine, Chungbuk National University, Cheongju, Korea. tgohkjs@chungbuk.ac.kr
- Publication Type:Comparative Study ; Original Article ; Randomized Controlled Trial
- Keywords:
Diabetes mellitus, type 2;
Glimepiride;
Metformin;
Vildagliptin
- MeSH:
Adamantane;
Blood Glucose;
Body Weight;
Diabetes Mellitus, Type 2;
Fasting;
Glucose;
Humans;
Hypoglycemia;
Incidence;
Metformin;
Nitriles;
Plasma;
Pyrrolidines;
Sulfonylurea Compounds;
Weight Gain
- From:Diabetes & Metabolism Journal
2011;35(5):529-535
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: The present study investigated the efficacy and safety of vildagliptin-metformin treatment compared to those of glimepiride-metformin treatment for type 2 diabetes. METHODS: In a randomized, open-label, comparative study, 106 patients with type 2 diabetes were enrolled. The primary endpoint was a reduction in HbA1c from baseline and secondary endpoints included fasting plasma glucose (FPG) or 2-hour postprandial glucose (2h-PPG) reduction from baseline, as well as HbA1c responder rate and HbA1c reduction according to baseline HbA1c category. RESULTS: Comparable HbA1c reduction was observed with a mean+/-standard deviation change from baseline to the 32-week endpoint of -0.94+/-1.15% in the vildagliptin group and -1.00+/-1.32% in the glimepiride group. A similar reduction in 2h-PPG (vildagliptin group 3.53+/-4.11 mmol/L vs. the glimepiride group 3.72+/-4.17 mmol/L) was demonstrated, and the decrements in FPG (vildagliptin group 1.54+/-2.41 mmol/L vs. glimepiride group 2.16+/-2.51 mmol/L) were not different between groups. The proportion of patients who achieved an HbA1c less than 7% at week 32 was 50.1% in the vildagliptin group and 56.0% in the glimepiride group. An average body weight gain of 2.53+/-1.21 kg in the glimepiride group was observed in contrast with the 0.23+/-0.69 kg weight gain noted in the vildagliptin group. A 10-fold lower incidence of hypoglycemia was demonstrated in the vildagliptin group, in addition to an absence of severe hypoglycemia. CONCLUSION: Vildagliptin-metformin treatment provided blood glucose control efficacy comparable to that of glimepiride-metformin treatment and resulted in better adverse event profiles with lower risks of hypoglycemia and weight gain.
